Sudan Loganathan
Stock Analyst at Stephens & Co.
(1.01)
# 3,595
Out of 4,732 analysts
24
Total ratings
35%
Success rate
-15.86%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Sudan Loganathan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BPMC Blueprint Medicines | Reiterates: Overweight | $140 | $110.05 | +27.21% | 2 | Jan 2, 2025 | |
| ELEV Elevation Oncology | Reiterates: Overweight | $5 | $0.71 | +602.94% | 2 | Dec 6, 2024 | |
| ATNM Actinium Pharmaceuticals | Reiterates: Overweight | $5 | $1.40 | +257.14% | 2 | Nov 19, 2024 | |
| CPRX Catalyst Pharmaceuticals | Initiates: Overweight | $35 | $22.78 | +53.64% | 1 | Nov 18, 2024 | |
| IDYA IDEAYA Biosciences | Initiates: Overweight | $51 | $22.18 | +129.94% | 1 | Nov 18, 2024 | |
| CCCC C4 Therapeutics | Initiates: Equal-Weight | $4 | $3.94 | +1.52% | 1 | Nov 18, 2024 | |
| KYMR Kymera Therapeutics | Initiates: Overweight | $65 | $40.61 | +60.06% | 1 | Nov 18, 2024 | |
| ARVN Arvinas | Initiates: Overweight | $55 | $18.05 | +204.71% | 1 | Nov 18, 2024 | |
| BCYC Bicycle Therapeutics | Initiates: Equal-Weight | $25 | $13.34 | +87.41% | 1 | Nov 8, 2024 | |
| ADCT ADC Therapeutics | Initiates: Overweight | $6 | $1.83 | +227.87% | 1 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $9.99 | +200.30% | 1 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $13 | $1.50 | +766.67% | 1 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $23 → $29 | $36.20 | -19.89% | 2 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $31 | $19.14 | +61.96% | 2 | Oct 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $14.31 | +74.70% | 2 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $0.53 | +843.40% | 2 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $2.08 | +861.54% | 1 | May 14, 2024 |
Blueprint Medicines
Jan 2, 2025
Reiterates: Overweight
Price Target: $140
Current: $110.05
Upside: +27.21%
Elevation Oncology
Dec 6, 2024
Reiterates: Overweight
Price Target: $5
Current: $0.71
Upside: +602.94%
Actinium Pharmaceuticals
Nov 19, 2024
Reiterates: Overweight
Price Target: $5
Current: $1.40
Upside: +257.14%
Catalyst Pharmaceuticals
Nov 18, 2024
Initiates: Overweight
Price Target: $35
Current: $22.78
Upside: +53.64%
IDEAYA Biosciences
Nov 18, 2024
Initiates: Overweight
Price Target: $51
Current: $22.18
Upside: +129.94%
C4 Therapeutics
Nov 18, 2024
Initiates: Equal-Weight
Price Target: $4
Current: $3.94
Upside: +1.52%
Kymera Therapeutics
Nov 18, 2024
Initiates: Overweight
Price Target: $65
Current: $40.61
Upside: +60.06%
Arvinas
Nov 18, 2024
Initiates: Overweight
Price Target: $55
Current: $18.05
Upside: +204.71%
Bicycle Therapeutics
Nov 8, 2024
Initiates: Equal-Weight
Price Target: $25
Current: $13.34
Upside: +87.41%
ADC Therapeutics
Nov 8, 2024
Initiates: Overweight
Price Target: $6
Current: $1.83
Upside: +227.87%
Nov 8, 2024
Initiates: Overweight
Price Target: $30
Current: $9.99
Upside: +200.30%
Nov 8, 2024
Initiates: Overweight
Price Target: $13
Current: $1.50
Upside: +766.67%
Oct 30, 2024
Maintains: Equal-Weight
Price Target: $23 → $29
Current: $36.20
Upside: -19.89%
Oct 14, 2024
Reiterates: Overweight
Price Target: $31
Current: $19.14
Upside: +61.96%
Aug 6, 2024
Reiterates: Overweight
Price Target: $25
Current: $14.31
Upside: +74.70%
May 24, 2024
Reiterates: Overweight
Price Target: $5
Current: $0.53
Upside: +843.40%
May 14, 2024
Initiates: Overweight
Price Target: $20
Current: $2.08
Upside: +861.54%